MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shumway, S. D.
Right arrow Articles by Miyamoto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shumway, S. D.
Right arrow Articles by Miyamoto, S.

Vol. 61, Issue 1, 177-185, January 2002

Evidence for Unique Calmodulin-Dependent Nuclear Factor-kappa B Regulation in WEHI-231 B Cells

Stuart D. Shumway, Craig M. Berchtold, Michael N. Gould, and Shigeki Miyamoto

Program in Cellular and Molecular Biology, Department of Pharmacology (S.D.S., S.M), and McArdle Laboratory for Cancer Research (C.M.B., M.N.G.), University of Wisconsin, Madison, Wisconsin

Immature B cells express constitutive nuclear factor-kappa B (NF-kappa B) activity and inhibition of this activity is associated with the induction of apoptotic cell death. Previous studies have implicated a calcium-dependent proteolysis of the NF-kappa B inhibitory protein Ikappa Balpha as critical in the maintenance of constitutive NF-kappa B activity in these cells. We tested whether modulation of diverse calcium-dependent processes affects the maintenance of constitutive NF-kappa B activity in the WEHI-231 immature B cell line. Calmodulin inhibitors, but not calcineurin inhibition, blocked both Ikappa Balpha turnover and the maintenance of constitutive NF-kappa B activity. Inhibition of NF-kappa B DNA binding activity by the calmodulin antagonist W13 also resulted in a loss of the expression of the NF-kappa B target gene, Ikappa Balpha . However, prolonged inhibition of NF-kappa B activity for up to 8 h did not lead to apoptotic induction in the WEHI-231 cells. Moreover, removal of calmodulin inhibitors resulted in the reappearance of constitutive NF-kappa B activity and the renewed expression of the Ikappa Balpha gene. Thus, calmodulin activity is a requirement for the continual turnover of Ikappa Balpha and the maintenance of constitutive NF-kappa B function in WEHI-231 cells. In addition, our findings suggest that inhibition of NF-kappa B activity does not lead to the immediate onset of apoptosis, indicating that prolonged inhibition of NF-kappa B-dependent gene expression is required to cause apoptosis of WEHI-231 B cells.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
BloodHome page
E. Vigorito, L. Gambardella, F. Colucci, S. McAdam, and M. Turner
Vav proteins regulate peripheral B-cell survival
Blood, October 1, 2005; 106(7): 2391 - 2398.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Berchtold, K.-S. Chen, S. Miyamoto, and M. N. Gould
Perillyl Alcohol Inhibits a Calcium-Dependent Constitutive Nuclear Factor-{kappa}B Pathway
Cancer Res., September 15, 2005; 65(18): 8558 - 8566.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. O'Connor, S. D. Shumway, I. J. Amanna, C. E. Hayes, and S. Miyamoto
Regulation of Constitutive p50/c-Rel Activity via Proteasome Inhibitor-Resistant I{kappa}B{alpha} Degradation in B Cells
Mol. Cell. Biol., June 1, 2004; 24(11): 4895 - 4908.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics